Early diagnosis of prostate cancer in finasteride treated BPH patients

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 693-696

  Tarle, Marko ^a   Kraus, Ognjen ^a   Trnski, Davor ^a   Reljic, Ante ^a   Ruzic, Boris ^a   Katusic, Josip ^a   Spajic, Boro ^a   Kusic, Zvonko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Benign prostatic hypertrophy; Early diagnosis; Finasteride therapy; Large prostate; Prostate cancer; Total PSA and FPSA serotests

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEROLOGY;

AGED; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0037233675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lieber MM: Pharmacological therapy for prostatism. Mayo Clin Proc 73: 590-596, 1998.
2. Wilson JD: The pathogenesis of benign prostatic hyperplasia. Am J Med 68: 152-167, 1990.
3. Saez C, Gonzales-Baena AC, Japon MA, Giraldez J, Sesura DI, Miranda G, Rodriguez-Vallejo JM, Gonzales-Esteban J and Torrubia F: Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 37: 84-90, 1998.
4. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD and Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
5. Saez C, Gonzales-Baena AC, Japon MA, Giraldez J, Segura DI, Rodriguez-Vallejo JM, Gonzales-Esteban J, Miranda G and Torrubia F: Expression of basic fiberoblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 40: 83-88, 1999.
6. Magoha GA: Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia. East Africa J Med 75: 260-263, 1998.
7. Schulman CC: Long-tern aspects of medical treatment of BPH. Eur Urol 40 (suppl 3): 8-12, 2000.
8. Guess HA, Gormley GJ, Stoner E and Oesterling JE: The effect of finasteride on prostate specific antigen: review of available data. J Urol 155: 3-9, 1996.
9. Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E and Partin AW: Influence of finasteride on free and total serum prostate specific antigen level in men with benign prostatic hyperplasia. J Urol 159: 449-453, 1998.
10. Ahel MZ, Kovacic K and Tarle M: Cross-correlation of serum chromogranin A, % FPSA and bone scans in prostate cancer diagnosis. Anticancer Res 2B: 1363-1366, 2001.
11. Grossklaus DJ, Shappell SB, Gautam S, Smith JA Jr and Cookson MS: Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol 165: 455-458, 2001.
12. Tarle M, Kraus O, Kraljic I, Trnski D, Anzulovic Z, Katusic J, Reljic A and Ruzic B: Subclinical detection of symptomatic BPH from prostate cancer in finasteride treated patients. J Tumor Marker Oncology 13: 32-33, 1998.
13. Tarle M, Reljic A, Kraus O, Kraljic I, Ruzic B and Trnski D: A novel procedure for the detection of prostate cancer in situ by applying finasteride therapy. Anticancer Res 18: 1959, 1998.
14. Yang XJ, Lecksell K, Short K, Gottesman J, Petersen L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J and Epstein JI: Does long term finasteride therapy affect the histological features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 53: 696-700, 1999.
15. Brawer MK, Lin DW, Williford WO, Jones K and Lepor H: Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 39: 234-239, 1999.